Compare Summit Therapeutics Inc (SMMT) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Yum! Brands, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Yum! Brands, Inc. trades at $144.69 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 2.8× Summit Therapeutics Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Yum! Brands, Inc. for 132 Days on average.
| SMMT | YUM | |
|---|---|---|
Market Cap | $13.71B | $39.02B |
Volume | 6,173,057 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $168.16 |
52-Week Low | $12.43 | $135.77 |
Typical Hold Time | 16 Days | 132 Days |
Enterprise Value | $13.04B | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
YUM trades at $144.82, up 3.18% today, with a bullish technical signal despite mixed indicators. Revenue grew to $8.21B in 2025, with net income of $1.56B and a strong net margin of 25.4%. The company recently sold Pizza Hut for $1.5B and announced a $0.75 dividend, reflecting strategic focus on core brands. Analysts maintain a consensus price target of $170.44, with 39% buy ratings.
YUM presents a stable investment with consistent earnings beats and dividend growth, but faces risks from high debt levels and competitive pressures. Upside is supported by analyst targets and operational efficiency, while macroeconomic headwinds and consumer spending trends pose challenges to sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
